COX-2 Selective NSAIDs
The structural differences between COX-1 and COX-2 allowed for the development of selective COX-2 inhibitors
E.g. Celecoxib (Roficoxib and Valdecoxib withdrawn)
Differ from most of traditional NSAIDs that inhibit both COX-1 and COX-2
However, etodolac, meloxicam and numelsulide display some level of COX-2 selectivity
Lower risk of the development of GI bleeding
No significant effects on platelets
Relative selectivity Figure (41.11) in Lippincott (pp.504)
However, (like traditional NSAIDs) May cause renal insufficiency and increase risk of hypertension
However, for patients who require chronic use of NSAIDs and are at high risk for NSAID—related gastroduodenal toxicity, primary therapy with a COX-2 selective inhibitor is a reasonable option
Celecoxib
Selective for COX-2.
At in-vivo concentrations, does not inhibit COX-1
Inhibition of COX-2 is time-dependent and reversible
Readily absorbed from GIT (peak= 3 hrs)
Extensively metabolised by liver. Excreted by feces and urine
T1/2= 11 hrs (taken once daily)
Adverse effects:
The most common: Abdominal pain, diarrhea and dyspepsia
Less gastroduodenal ulcer than naproxen, diclofenac or ibuprofen
Kideny toxicity may occur (like with ither NSAIDs)
Celecoxib is contraindicated in patients allergic to sulfonamides
Selective COX-2 inhibitors should be avoided in patients with renal insufficiency, severe heart disease, volume depletion and/or hepatic failure
Patients with HX of anaphylactoid reactions to aspirin or nonselective NSAIDs may have similar effects..